SLE (Systemic Lupus) Clinical Trial
Official title:
BElimumab corticoSteroids Sparing Treatment in Systemic Lupus
BELIMUMAB, anti-BLyS human monoclonal antibody, is the first immunotherapy used for the treatment of systemic lupus erythematosus (SLE) which was licensed in 2011 in France. Currently, Belimumab is reimbursed for the treatment of active SLEwith autoantibody-positive after intolerant or initial failure of first-line traitment (anti malaria, non-steroidal anti-inflammatory drugs, glucocorticoids and/ou immunomodulatory agents). EUropean League Against Rheumatism (EULAR) suggest the following terminology of "low dose" when steroids are less than 7.5 mg/day (prednisone equivalent) because this dose range is often used for maintenance therapy for many rheumatic diseases requiring glucocorticoids and it is relatively few adverse effects. In patients with SLE, a significant proportion of the damage could be attributed to corticosteroid therapy, and this damage accumulated over time. Thanks to randomised and subgroups trials, post-hoc analysis , BELIMUMAB seems to be interesting in the maintain of lowest possible dose of glucocorticoids. However, these studies were not design with this aim, so it is impossible to conclude. Thus, BELIMUMAB seems to be very interesting treatment to redcuce glucocorticoids level. We conduce a multicentric French study in real-life settings, to assess the ability of belimumab to achieve low-dose of steroids.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06063668 -
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
|
||
| Recruiting |
NCT04866615 -
Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA
|
||
| Not yet recruiting |
NCT04645225 -
Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
|
||
| Recruiting |
NCT04604990 -
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
|
||
| Recruiting |
NCT06150651 -
Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.
|
Phase 1 | |
| Recruiting |
NCT06056921 -
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
|
Phase 1 | |
| Recruiting |
NCT05866861 -
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
|
Phase 1 | |
| Recruiting |
NCT06294236 -
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
|
Phase 1 |